Drug Search Results
More Filters [+]

Entinostat

Alternative Names: entinostat, ms-275, sndx-275, bay 86-5274, khk-2375, khk2375, khk 2375
Latest Update: 2024-09-04
Latest Update Note: Clinical Trial Update

Product Description

Syndax is developing Entinostat. Entinostat, is a selective, oral, once-weekly, class I HDAC inhibitor that has been studied in multiple solid tumors in combination with hormone therapy and several approved PD-1/PD-L1 antagonists. (Sourced from: https://syndax.com/pipeline/entinostat/)

Mechanisms of Action: HDAC Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Syndax
Company Location: WALTHAM MA 02451
Company CEO: Michael A. Metzger
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Entinostat

Countries in Clinic: Israel, Japan, Korea, Sweden, United States

Active Clinical Trial Count: 9

Highest Development Phases

Phase 2: Breast Cancer|Colorectal Cancer|Lymphoma|Melanoma|Non-Small-Cell Lung Cancer|Renal Cell Carcinoma|Uveal Melanoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

NCT03179930

P2

Active, not recruiting

Lymphoma

2025-06-01

MORPHEUS HR+BC

P2

Active, not recruiting

Breast Cancer

2024-09-12

NA_00084192

P2

Completed

Non-Small-Cell Lung Cancer

2023-04-04

PEMDAC

P2

Completed

Uveal Melanoma

2023-01-31

Recent News Events